Peramivir Patent Expiration

1. Rapivab patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6503745 BIOCRYST Cyclopentane and cyclopentene compounds and use for detecting influenza virus
Nov, 2019

(4 years ago)

US6562861 BIOCRYST Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors
Dec, 2023

(6 months ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10391075 BIOCRYST Antiviral treatments
Feb, 2027

(2 years from now)

US8778997 BIOCRYST Antiviral treatments
May, 2027

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 19, 2019
New Patient Population(NPP) Sep 20, 2020

NCE-1 date: 19 December, 2018

Market Authorisation Date: 19 December, 2014

Treatment: Treatment of acute uncomplicated influenza in patients 6 months and older


More Information on Dosage

RAPIVAB family patents

Family Patents